N@N

Eurand N.V.: Eurand Announces Conference Call on Fourth Quarter and Full-Year 2008 Financial Results

_{//health-fitness.news-articles.net/content/2009/ .. uarter-and-full-year-2008-financial-results.html}
^{Published in Health and Fitness on Monday, February 9th 2009 at 10:51 GMT, Last Modified on 2009-02-09 10:51:49 by Market Wire}  

AMSTERDAM, THE NETHERLANDS--(Marketwire - February 9, 2009) - Eurand N.V. (NASDAQ: [ EURX ]), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, will host a conference call on Thursday, March 5, 2009 at 8:30 a.m. ET to discuss its fourth quarter and full-year 2008 financial results. The conference call will be hosted by Gearóid Faherty, Chairman and Chief Executive Officer, and Mario Crovetto, Chief Financial Officer.

The conference call schedule is as follows:

7:00 a.m. ET: Fourth quarter 2008 financial results released

8:20 a.m. ET: Dial in to participate in the conference call:

 -- U.S. Participants dial 1-877-407-9039 -- International Participants dial +1-201-689-8470 

8:30 a.m. ET: Conference call begins

Call Replay: A replay of the call will be available from 11:30 a.m. ET on March 5, 2009 until April 5, 2009. The Account Number is: 3055; Conference ID Number: 312757.

 -- U.S. Participants dial 1-877-660-6853 -- International Participants dial +1-201-612-7415 

Webcast: A live webcast of the call also will be available from the Investor Relations section of the corporate web site at [ www.eurand.com ]. Following the live webcast, the archived version of the call will be available at the same URL until April 5, 2009.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at [ www.eurand.com ].